Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
The purpose of this study is to see if delivering laser light directly to the prostate to activate a light-sensitive drug is a safe and effective treatment for prostate cancer that has come back after radiation therapy. The goal of this treatment is to eliminate any remaining prostate cancer cells. This approach is a form of photodynamic therapy (PDT).
Researchers are comparing RMC-6236 with standard therapy in people with advanced pancreatic cancer. The people in this study have pancreatic cancer that has metastasized (spread) and keeps growing even after treatment.
Researchers are assessing different doses of FT825 alone or with cetuximab to treat people with advanced solid tumors. Their tumors have high levels of the HER2 protein. Altered HER2 proteins can fuel cancer growth. 
Researchers want to find the best dose of EVM14 when used alone or with pembrolizumab in people with solid tumors. The people in this study have a solid tumor that keeps growing after treatment and has spread. This study includes people with:
Breast cancer (TNBC) and non-small cell lung cancer (NSCLC) that spread to other parts of the body (metastasize) are usually treated with chemotherapy, immunotherapy, targeted therapies, and/or radiation therapy. In this study, researchers want to see if using stereotactic body radiosurgery (SBRT) to all metastatic tumors plus standard therapy is more effective than standard therapy alone in patients with oligometastatic TNBC or NSCLC (five or fewer metastatic tumors).
Researchers are seeking the best dose of revumenib (SNDX-5613) to give with chemotherapy in people with acute myeloid leukemia (AML). The people in this study have AML that has not yet been treated. In addition, their cancers have a mutation (change) in the KMT2Ar, NPM1c, or NUP98r gene.
Researchers in this study are exploring the feasibility of making an immunotherapy in a laboratory using white blood cells (called lymphocytes or T cells) collected from the tumor of a patient with metastatic uveal melanoma. This is called autologous tumor-infiltrating lymphocyte (TIL) therapy. The TIL therapy being assessed in this study is called LN-144, and it is designed to activate white blood cells to attack the tumor.
Researchers want to see if ruxolitinib works well as a treatment for T-cell large granular lymphocytic leukemia (T-LGLL). T-LGLL is a rare cancer of white blood cells called lymphocytes. The people in this study have T-LGLL that keeps growing even with treatment.
Researchers are doing this study to see how well sotorasib gets into metastatic brain tumors. The people in this study have tumors in the brain that have spread there from other parts of the body. They are planning to have the brain metastases removed with surgery. In addition, their tumors have a mutation (change) in the KRAS gene (KRAS G12C+).
Researchers are comparing different treatments for non-muscle invasive bladder cancer (NMIBC). The people in this study have NMIBC that keeps growing after treatment with an immunotherapy called Bacillus Calmette-Guerin (BCG). They do not want surgery to remove the bladder (radical cystectomy).
